The trial, titled IAVI G002, is being conducted in partnership with IAVI, a nonprofit scientific research organization. It is testing a vaccine that delivers HIV-specific antigens to the body with the goal of inducing an immune response.
VIEW MORE : https://bit.ly/1breakingnews
